Abstract：
Pancreatic cancer (PC) has the poorest prognosis among digestive cancers; only 15-20% of cases are resectable at diagnosis. This review explores multidisciplinary treatments for advanced PC, emphasizing resectability classification and treatment strategies. For locally advanced unresectable PC, systemic chemotherapy using modified FOLFIRINOX and gemcitabine with albumin-bound paclitaxel is standard, while the role of chemoradiation is debated. Induction chemotherapy followed by chemoradiation may be a promising therapy. Conversion surgery after initial chemotherapy or chemoradiotherapy offers favorable survival, however criteria for conversion need further refinements. For metastatic PC, clinical trials using immune checkpoint inhibitors and molecular targeted therapies are ongoing. Multidisciplinary approaches and further research are crucial for optimizing treatment and improving outcomes for advanced PC.
摘要：
胰腺癌（PC）在消化系统癌症中预后最差；只有15-20％的病例在诊断时可以切除。这篇综述探讨了先进PC的多学科治疗，强调可切除性分类和治疗策略。对于本地高级不可切除的PC，使用改良FOLFIRINOX和吉西他滨联合白蛋白结合型紫杉醇的全身化疗是标准的,而放化疗的作用是有争议的。诱导化疗后放化疗可能是一种有前途的治疗方法。初次化疗或放化疗后的转换手术可提供良好的生存率，然而，转换标准需要进一步完善。对于转移性PC，使用免疫检查点抑制剂和分子靶向疗法的临床试验正在进行中.多学科方法和进一步研究对于优化高级PC的治疗和改善结果至关重要。
